Preliminary phase I results from a first-in-human study of ZG006, a trispecific anti-T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with advanced small cell lung cancer or neuroendocrine carcinoma

被引：0
|
作者：
Wang, Q. [1 ]
Chai, X. [2 ]
Lin, R. [3 ]
Zheng, L. [4 ]
Cao, D. [5 ]
Qu, X. [6 ]
Liu, L. [7 ]
Wu, L. [8 ]
Mou, H. [9 ]
Xu, Q. [10 ]
Shi, J. [11 ]
机构：
[1] Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Resp, Zhengzhou, Peoples R China
[2] ChangSha TaiHe Hosp, Dept Oncol, Changsha, Peoples R China
[3] Fujian Canc Hosp, Dept Abdominal Oncol, Fujian, Peoples R China
[4] Sichuan Univ, West China Hosp, Clin Trial Ctr, Chengdu, Peoples R China
[5] Sichuan Univ, West China Hosp, Dept Abdominal Oncol, Chengdu, Peoples R China
[6] China Med Univ, Hosp 1, Dept Med Oncol, Shenyang, Peoples R China
[7] Jilin Univ, China Japan Union Hosp, Phase Clin Trial Ctr 1, Changchun, Peoples R China
[8] Shulan Hangzhou Hosp, Dept Hepatobiliary & Pancreat Surg, Hangzhou, Peoples R China
[9] Shulan Hangzhou Hosp, Dept Oncol, Hangzhou, Peoples R China
[10] Zhejiang Canc Hosp, Dept Hepatobiliary & Pancreat Gastroenterol, Hangzhou, Peoples R China
[11] Linyi Canc Hosp, Dept Med Oncol, Linyi, Shandong, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.752
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
686TiP
引用
收藏
页码：S532 / S533
页数：2
相关论文
共 50 条
  • [41] ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China
    Hu, Chunfang
    Dong, Jiyan
    Liu, Li
    Liu, Jingbo
    Sun, Xujie
    Teng, Fei
    Wang, Xin
    Ying, Jianming
    Li, Junling
    Xing, Puyuan
    Yang, Lin
    THORACIC CANCER, 2022, 13 (03) : 338 - 345
  • [42] Phase 1b study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTEimmune-oncology therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).
    Aggarwal, Rahul Raj
    Aparicio, Ana
    Heidenreich, Axel
    Sandhu, Shahneen Kaur
    Zhang, Yiran
    Salvati, Mark
    Shetty, Aditya
    Sadraei, Nooshin Hashemi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] TREM1/DAP12 based novel multiple chain CAR-T cells targeting DLL3 show robust anti-tumour efficacy for small cell lung cancer
    Nie, Fengqi
    Chen, Yuli
    Hu, Yanming
    Huang, Peng
    Shi, Xuefei
    Cai, Jingsheng
    Qiu, Mantang
    Wang, Enxiu
    Lu, Kaihua
    Sun, Ming
    IMMUNOLOGY, 2024, 172 (03) : 362 - 374
  • [44] Randomized Phase-3 Study: Tarlatamab, a DLL3-targeting Bispecific T-cell engager (BiTE), Compared to Standard-of-Care in Relapsed Small Cell Lung Cancer (DeLLphi-304)
    Rodriguez, Luis Paz -Ares
    Felip, Enriqueta
    Ahn, Myung-Ju
    Blackhall, Fiona Helen
    Borghaei, Hossein
    Cho, Byoung Chul
    Johnson, Melissa Lynne
    Ramalingam, Suresh S.
    Reck, Martin
    Jiang, Tony
    Ju, Chia-Hsin
    Minocha, Mukul
    Mukherjee, Sujoy
    Suri, Gaurav
    Recondo, Gonzalo
    Martinezi, Pablo
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E34 - E34
  • [45] Interim results from a phase I/II study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine neoplasms (NEN)
    Choudhury, N.
    Jain, P.
    Dowlati, A.
    Thompson, J.
    Johnson, M. L.
    Mamdani, H.
    Sanborn, R. E.
    Schenk, E. L.
    Aggarwal, R.
    Sankar, K.
    Walker, L. N.
    Anand, B.
    Beltran, H.
    ANNALS OF ONCOLOGY, 2023, 34 : S486 - S486
  • [46] DareonTM-5: An open-label phase 2 trial of BI 764532, a DLL3-targeting T-cell engager, in patients (pts) with relapsed/refractory small cell lung cancer or other neuroendocrine carcinomas
    Gambardella, Valentina
    Greystoke, Alastair
    Reck, Martin
    Liu, Meiruo
    Mueller, Martha
    Duenzinger, Ulrich
    Bergsland, Emily B.
    Owonikoko, Taofeek
    CANCER RESEARCH, 2024, 84 (07)
  • [47] Interim results of an ongoing phase 1/2a study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other neuroendocrine cancers.
    Johnson, Melissa Lynne
    Dy, Grace K.
    Mamdani, Hirva
    Dowlati, Afshin
    Schoenfeld, Adam Jacob
    Pacheco, Jose Maria
    Sanborn, Rachel E.
    Menon, Smitha Patiyil
    Santiago, Linda
    Yaron, Yifah
    Beltran, Himisha
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [48] Impact of patient specific factors on exposures of tarlatamab, a half-life extended DLL3-directed bispecific T-cell engager in patients with advanced small cell lung cancer
    Kong, Stephanie M.
    Minocha, Mukul
    Chen, Po-Wei
    Martinez, Pablo
    Anderson, Erik S.
    Parkes, Amanda
    Houk, Brett E.
    Lin, Chih-Wei
    CANCER RESEARCH, 2024, 84 (06)
  • [49] A phase I/II, first-in-human, open-label, dose-escalation study of TAK-186, an EGFR 3 CD3ε COBRA T cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors
    Weickhardt, A. J.
    Frentzas, S.
    Lemech, C.
    Srimani, J.
    Yin, J.
    Trepicchio, W. L.
    Gorgun, C.
    Kichenadasse, G.
    ANNALS OF ONCOLOGY, 2023, 34 : S492 - S492
  • [50] Updated results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC)
    Beltran, Himisha
    Johnson, Melissa Lynne
    Jain, Prantesh
    Schenk, Erin L.
    Sanborn, Rachel E.
    Thompson, Jonathan Robert
    Dowlati, Afshin
    Mamdani, Hirva
    Aggarwal, Rahul Raj
    Anand, Banmeet S.
    Gramza, Ann W.
    Choudhury, Noura J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345